Immage Biotherapeutics IMMG · USD

Its shares trade under the ticker IMMG. It has been listed since 13 February 2014.

Immage Biotherapeutics Corp. is a biotechnology company, which develops novel immunotherapy biologics to treat various cancers. The company is headquartered in Bethesda, Maryland. The company went IPO on 2014-02-13. The firm is engaged in developing cancer immunotherapy through development of cutting-edge immunotherapy candidates using bioinformatics and outsourced laboratory resources. The company is focused on developing immunotherapy biologics to treat various cancers. The firm develops, markets and licenses its immunotherapy candidate for melanoma-associated antigen-A (MAGE A). The firm plans to focus on the development of immunotherapy for breast and prostate cancer. The firm focuses on developing a fusion/hybrid antigen cancer vaccine that would not only be human leukocyte antigen (HLA) free, but also be effective to all the isomers associated with MAGE A, from 1 to 11, and the identification and development of immunotherapy candidates from its intellectual property library for the preparation for human clinical trials using a viral vector construct.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Anton DormerChairman of the Board, Chief Scientific Officer, since 2015
• Mr. Zhi Cong MouPresident, Chief Executive Officer, Treasurer, Secretary, Director, since 2015
• Mr. Elton NormanChief Financial Officer, Director, since 2015
• Mr. Mahesh NarayananChief Operating Officer, Director, since 2015
• Mr. Daniel AchinkoVice President - Bioformatics

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.